See more : Shapir Engineering and Industry Ltd (SPEN.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Guardion Health Sciences, Inc. (GHSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Guardion Health Sciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- CPI Aerostructures, Inc. (CVU) Income Statement Analysis – Financial Results
- ALFOT Technologies Co., Ltd. (4553.TWO) Income Statement Analysis – Financial Results
- Shree Ganesh Remedies Limited (SGRL.BO) Income Statement Analysis – Financial Results
- SpiceJet Limited (SPICEJET.BO) Income Statement Analysis – Financial Results
- Nxera Pharma Co., Ltd. (4565.T) Income Statement Analysis – Financial Results
Guardion Health Sciences, Inc. (GHSI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.guardionhealth.com
About Guardion Health Sciences, Inc.
Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 12.25M | 11.05M | 7.23M | 1.89M | 902.94K | 942.15K | 437.35K | 141.03K | 112.81K | 164.58K | 260.36K |
Cost of Revenue | 6.85M | 6.53M | 4.12M | 1.95M | 341.32K | 398.18K | 175.47K | 75.70K | 50.07K | 145.53K | 168.88K |
Gross Profit | 5.39M | 4.52M | 3.11M | -56.79K | 561.62K | 543.97K | 261.88K | 65.33K | 62.74K | 19.05K | 91.48K |
Gross Profit Ratio | 44.04% | 40.91% | 43.00% | -3.01% | 62.20% | 57.74% | 59.88% | 46.32% | 55.61% | 11.58% | 35.14% |
Research & Development | 150.68K | 193.80K | 64.36K | 160.98K | 194.31K | 231.85K | 259.46K | 64.03K | 401.91K | 43.44K | 259.79K |
General & Administrative | 7.48M | 9.58M | 11.20M | 6.83M | 7.43M | 4.93M | 4.68M | 3.31M | 5.61M | 638.00K | 616.70K |
Selling & Marketing | 1.70M | 2.07M | 2.32M | 1.45M | 1.87M | 1.52M | 599.93K | 389.11K | 180.13K | 46.77K | 51.60K |
SG&A | 9.19M | 11.65M | 13.53M | 8.28M | 9.30M | 6.46M | 5.28M | 3.70M | 5.79M | 684.77K | 668.30K |
Other Expenses | 394.55K | 3.57M | 10.14M | 0.00 | 1.22M | 0.00 | 0.00 | 174.04K | -1.70M | 0.00 | 0.00 |
Operating Expenses | 9.73M | 11.84M | 13.59M | 8.45M | 9.50M | 6.69M | 5.54M | 3.76M | 6.19M | 728.21K | 928.09K |
Cost & Expenses | 16.58M | 18.37M | 17.72M | 10.39M | 9.84M | 7.09M | 5.72M | 3.84M | 6.24M | 873.74K | 1.10M |
Interest Income | 379.52K | 152.57K | 1.80K | 7.27K | 258.37K | 0.00 | 0.00 | 0.00 | 0.00 | 611.34K | 406.07K |
Interest Expense | 0.00 | 15.35M | 0.00 | 7.27K | 258.37K | 2.29K | 23.73K | 1.10M | 752.95K | 0.00 | 0.00 |
Depreciation & Amortization | 19.42K | 1.25M | 910.37K | 219.60K | 625.79K | 295.67K | 118.82K | 60.13K | 53.74K | 43.23K | 8.84K |
EBITDA | -3.92M | -6.07M | -9.70M | -8.34M | -9.99M | -7.47M | -5.16M | -4.58M | -8.03M | -665.92K | -827.77K |
EBITDA Ratio | -32.02% | 15.22% | -132.36% | -438.27% | -966.13% | -620.71% | -1,180.44% | -2,578.07% | -6,892.95% | -404.61% | -317.94% |
Operating Income | -4.34M | 432.68K | -10.48M | -8.55M | -8.93M | -6.14M | -5.28M | -3.95M | -6.39M | -709.15K | -836.61K |
Operating Income Ratio | -35.40% | 3.92% | -144.94% | -452.51% | -989.37% | -652.09% | -1,207.60% | -2,797.79% | -5,663.22% | -430.88% | -321.33% |
Total Other Income/Expenses | 4.49M | 2.50M | 1.80K | -19.93K | -381.37K | -1.62M | -23.73K | -1.80M | -2.45M | -611.34K | -406.07K |
Income Before Tax | 158.03K | -14.92M | -24.75M | -8.57M | -10.88M | -7.77M | -5.31M | -5.75M | -8.84M | -1.32M | -1.24M |
Income Before Tax Ratio | 1.29% | -135.05% | -342.11% | -453.56% | -1,204.77% | -824.43% | -1,213.03% | -4,076.04% | -7,837.26% | -802.33% | -477.30% |
Income Tax Expense | 0.00 | 15.35M | 672.79K | 7.27K | 258.37K | -1.62M | 0.00 | 1.10M | -946.66K | 0.00 | 0.00 |
Net Income | 158.03K | -30.28M | -24.75M | -8.58M | -11.14M | -7.77M | -5.31M | -5.75M | -8.84M | -1.32M | -1.24M |
Net Income Ratio | 1.29% | -274.01% | -342.11% | -453.95% | -1,233.38% | -824.43% | -1,213.03% | -4,076.04% | -7,837.26% | -802.33% | -477.30% |
EPS | 0.12 | -27.01 | -52.23 | -180.53 | -91.61 | -105.39 | -72.60 | -78.66 | -120.98 | -73.21 | -68.90 |
EPS Diluted | 0.12 | -27.01 | -52.23 | -180.53 | -91.61 | -105.09 | -72.60 | -78.66 | -120.98 | -73.21 | -68.90 |
Weighted Avg Shares Out | 1.27M | 1.12M | 473.77K | 47.52K | 121.56K | 73.70K | 73.08K | 73.08K | 73.08K | 18.04K | 18.04K |
Weighted Avg Shares Out (Dil) | 1.27M | 1.12M | 473.77K | 47.52K | 121.56K | 73.91K | 73.08K | 73.08K | 73.08K | 18.04K | 18.04K |
FH Kärnten Personalia: Michael Suppanz ist neuer Leiter des Studiengangs Physiotherapie
Excella Awarded CIO-SP3 Small Business Contract
How to live longer: The hot beverage proven to boost life expectancy
Extra 170 nurses trained to care for the most sick during Covid-19 crisis
JTC Team and LaVoieHealthScience to Host Virtual Investor Summit on April 22 and 23, 2020
JTC Team and LaVoieHealthScience to Host Virtual Investor Summit on April 22 and 23, 2020
How university is helping NHS fight Covid-19 crisis
Fourth university in region announces end to face-to-face teaching
University of Liverpool cancels all lectures over coronavirus fears
The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates
Source: https://incomestatements.info
Category: Stock Reports